Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Prognostic and predictive value of Pleckstrin homology-like domain, family A family members in breast cancer

Full text
Author(s):
Show less -
Mangone, Flavia R. [1, 2] ; Valoyes, Maira A. V. [1, 2] ; do Nascimento, Renan G. [1, 2] ; Conceicao, Mercia P. F. [1, 2] ; Bastos, Daniel R. [1, 2] ; Pavanelli, Ana C. [1, 2] ; Soares, Ibere C. [3] ; de Mello, Evandro S. [3] ; Nonogaki, Suely [4] ; Osorio, Cynthia A. B. [4] ; Nagai, Maria A. [1, 2]
Total Authors: 11
Affiliation:
[1] Univ Sao Paulo, Dept Radiol & Oncol, Fac Med, Discipline Oncol, BR-01246903 Sao Paulo - Brazil
[2] Canc Inst Sao Paulo, Ctr Translat Res Oncol, Lab Mol Genet, BR-01246000 Sao Paulo - Brazil
[3] AC Camargo Canc Ctr, Dept Pathol Anat, BR-01509020 Sao Paulo - Brazil
[4] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP, Dept Pathol, Inst Canc, BR-01246903 Sao Paulo - Brazil
Total Affiliations: 4
Document type: Journal article
Source: BIOMARKERS IN MEDICINE; v. 14, n. 16, p. 1539-1554, NOV 2020.
Web of Science Citations: 0
Abstract

Aim: The PHLDA (pleckstrin homology like domain, family A) gene family encodes proteins capable of inhibiting AKT (serine/threonine kinase) signaling through phosphoinositol binding competition. Results \& methodology: Using in silico analysis, we found that Luminal A and B patients' short relapse-free survival was associated with low PHLDA1 or PHLDA3 and high PHLDA2 expression. In a cohort of 393 patients with luminal breast cancer evaluated by immunohistochemistry on tissue microarrays, we found a direct association of PHLDA3 expression with hormonal therapy response (p = 0.013). Conclusion: Our findings provide new information on the role played by the PHLDA family members as prognostic markers in breast cancer, and more importantly, we provide evidence that they might also predict a response to endocrine therapy. (AU)

FAPESP's process: 19/05252-4 - Characterization of new predictive biomarkers of response to endocrine therapy and HER2 inhibitors in breast cancer
Grantee:Maria Aparecida Nagai
Support type: Regular Research Grants